Our analysis unveiled that COAD patients exhibiting elevated expression levels of CDCA2, CDCA3, CDCA4, CDCA5, CDCA7, and CDCA8 were predisposed to derive greater therapeutic benefits from a range of drugs, excluding PD-0325901, RDEA119, Trametinib, and Selumtinib. This evidence concerns the gene CDCA2 and colon adenocarcinoma.